Conditions: Non-small Cell Lung Cancer
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 226
Healthy volunteers: no

Brief summary:
To investigate efficacy and safety of pemetrexed as second or third line therapy in patients with non-small cell lung cancer (NSCLC).

Detailed description:

Arms:
arm 1: Pemetrexed 500 mg/m2 arm 2: Pemetrexed 1000 mg/m2

Interventions: intervention 1: Pemetrexed 500 mg/m2 intervention 2: Pemetrexed 1000 mg/m2
Intervention descriptions: intervention 1: 500 mg/m2, intravenous (IV), every 21 days, one year from registration date intervention 2: 1000 mg/m2, intravenous (IV), every 21 days, one year from registration date

Protocol document: